CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I

The treatment choice of differentiated thyroid cancer resistant to therapy 131I to be restricted just to systemic methods. Traditional chemotherapy demonstrated no clinically relevant effectiveness but high toxicity. With the introduction into clinical practice of multi-kinase inhibitor was able to...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	P. A. Isaev [verfasserIn] P. O. Rumyantsev [verfasserIn] V. V. Polkin [verfasserIn] A. A. Ilyin [verfasserIn] D. Yu. Syomin [verfasserIn] T. A. Agababyan [verfasserIn] S. V. Vasilkov [verfasserIn] V. S. Medvedev [verfasserIn]

Format:	E-Artikel
Sprache:	Russisch

Erschienen:	2015

Schlagwörter:	the differentiated thyroid cancer resistant to therapy 131i decision multi-kinase inhibitor nexavar (sorafenib)

Übergeordnetes Werk:	In: Опухоли головы и шеи - ABV-press, 2016, (2015), 2, Seite 46-50
Übergeordnetes Werk:	year:2015 ; number:2 ; pages:46-50

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.17650/2222-1468-2014-0-2-46-50

Katalog-ID:	DOAJ085436208

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ085436208
003	DE-627
005	20230410120617.0
007	cr uuu---uuuuu
008	230311s2015 xx \|\|\|\|\|o 00\| \|\|rus c
024	7		\|a 10.17650/2222-1468-2014-0-2-46-50 \|2 doi
035			\|a (DE-627)DOAJ085436208
035			\|a (DE-599)DOAJa3b54c5c44cc4a929dc1b83bea2764f9
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a rus
050		0	\|a RC254-282
100	0		\|a P. A. Isaev \|e verfasserin \|4 aut
245	1	0	\|a CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I
264		1	\|c 2015
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a The treatment choice of differentiated thyroid cancer resistant to therapy 131I to be restricted just to systemic methods. Traditional chemotherapy demonstrated no clinically relevant effectiveness but high toxicity. With the introduction into clinical practice of multi-kinase inhibitor was able to significantly improve treatment outcomes.The paper demonstrated two patients with the incurable of differentiated thyroid cancer resistant to therapy 131I. All patients received Nexavar (sorafenib). Its therapeutic effectiveness varied from partial response to long-term stabilization.
650		4	\|a the differentiated thyroid cancer resistant to therapy 131i
650		4	\|a decision
650		4	\|a multi-kinase inhibitor
650		4	\|a nexavar (sorafenib)
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
700	0		\|a P. O. Rumyantsev \|e verfasserin \|4 aut
700	0		\|a V. V. Polkin \|e verfasserin \|4 aut
700	0		\|a A. A. Ilyin \|e verfasserin \|4 aut
700	0		\|a D. Yu. Syomin \|e verfasserin \|4 aut
700	0		\|a T. A. Agababyan \|e verfasserin \|4 aut
700	0		\|a S. V. Vasilkov \|e verfasserin \|4 aut
700	0		\|a V. S. Medvedev \|e verfasserin \|4 aut
773	0	8	\|i In \|t Опухоли головы и шеи \|d ABV-press, 2016 \|g (2015), 2, Seite 46-50 \|w (DE-627)1760616370 \|x 24114634 \|7 nnns
773	1	8	\|g year:2015 \|g number:2 \|g pages:46-50
856	4	0	\|u https://doi.org/10.17650/2222-1468-2014-0-2-46-50 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/a3b54c5c44cc4a929dc1b83bea2764f9 \|z kostenfrei
856	4	0	\|u https://ogsh.abvpress.ru/jour/article/view/52 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2222-1468 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2411-4634 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|j 2015 \|e 2 \|h 46-50

Indexfelder

author_variant	p a i pai p o r por v v p vvp a a i aai d y s dys t a a taa s v v svv v s m vsm
matchkey_str	article:24114634:2015----::lnclxeinefeaasrfnbplctoiptetwtmtsaidfeetaetyo
hierarchy_sort_str	2015
callnumber-subject-code	RC
publishDate	2015
allfields	10.17650/2222-1468-2014-0-2-46-50 doi (DE-627)DOAJ085436208 (DE-599)DOAJa3b54c5c44cc4a929dc1b83bea2764f9 DE-627 ger DE-627 rakwb rus RC254-282 P. A. Isaev verfasserin aut CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The treatment choice of differentiated thyroid cancer resistant to therapy 131I to be restricted just to systemic methods. Traditional chemotherapy demonstrated no clinically relevant effectiveness but high toxicity. With the introduction into clinical practice of multi-kinase inhibitor was able to significantly improve treatment outcomes.The paper demonstrated two patients with the incurable of differentiated thyroid cancer resistant to therapy 131I. All patients received Nexavar (sorafenib). Its therapeutic effectiveness varied from partial response to long-term stabilization. the differentiated thyroid cancer resistant to therapy 131i decision multi-kinase inhibitor nexavar (sorafenib) Neoplasms. Tumors. Oncology. Including cancer and carcinogens P. O. Rumyantsev verfasserin aut V. V. Polkin verfasserin aut A. A. Ilyin verfasserin aut D. Yu. Syomin verfasserin aut T. A. Agababyan verfasserin aut S. V. Vasilkov verfasserin aut V. S. Medvedev verfasserin aut In Опухоли головы и шеи ABV-press, 2016 (2015), 2, Seite 46-50 (DE-627)1760616370 24114634 nnns year:2015 number:2 pages:46-50 https://doi.org/10.17650/2222-1468-2014-0-2-46-50 kostenfrei https://doaj.org/article/a3b54c5c44cc4a929dc1b83bea2764f9 kostenfrei https://ogsh.abvpress.ru/jour/article/view/52 kostenfrei https://doaj.org/toc/2222-1468 Journal toc kostenfrei https://doaj.org/toc/2411-4634 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2015 2 46-50
spelling	10.17650/2222-1468-2014-0-2-46-50 doi (DE-627)DOAJ085436208 (DE-599)DOAJa3b54c5c44cc4a929dc1b83bea2764f9 DE-627 ger DE-627 rakwb rus RC254-282 P. A. Isaev verfasserin aut CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The treatment choice of differentiated thyroid cancer resistant to therapy 131I to be restricted just to systemic methods. Traditional chemotherapy demonstrated no clinically relevant effectiveness but high toxicity. With the introduction into clinical practice of multi-kinase inhibitor was able to significantly improve treatment outcomes.The paper demonstrated two patients with the incurable of differentiated thyroid cancer resistant to therapy 131I. All patients received Nexavar (sorafenib). Its therapeutic effectiveness varied from partial response to long-term stabilization. the differentiated thyroid cancer resistant to therapy 131i decision multi-kinase inhibitor nexavar (sorafenib) Neoplasms. Tumors. Oncology. Including cancer and carcinogens P. O. Rumyantsev verfasserin aut V. V. Polkin verfasserin aut A. A. Ilyin verfasserin aut D. Yu. Syomin verfasserin aut T. A. Agababyan verfasserin aut S. V. Vasilkov verfasserin aut V. S. Medvedev verfasserin aut In Опухоли головы и шеи ABV-press, 2016 (2015), 2, Seite 46-50 (DE-627)1760616370 24114634 nnns year:2015 number:2 pages:46-50 https://doi.org/10.17650/2222-1468-2014-0-2-46-50 kostenfrei https://doaj.org/article/a3b54c5c44cc4a929dc1b83bea2764f9 kostenfrei https://ogsh.abvpress.ru/jour/article/view/52 kostenfrei https://doaj.org/toc/2222-1468 Journal toc kostenfrei https://doaj.org/toc/2411-4634 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2015 2 46-50
allfields_unstemmed	10.17650/2222-1468-2014-0-2-46-50 doi (DE-627)DOAJ085436208 (DE-599)DOAJa3b54c5c44cc4a929dc1b83bea2764f9 DE-627 ger DE-627 rakwb rus RC254-282 P. A. Isaev verfasserin aut CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The treatment choice of differentiated thyroid cancer resistant to therapy 131I to be restricted just to systemic methods. Traditional chemotherapy demonstrated no clinically relevant effectiveness but high toxicity. With the introduction into clinical practice of multi-kinase inhibitor was able to significantly improve treatment outcomes.The paper demonstrated two patients with the incurable of differentiated thyroid cancer resistant to therapy 131I. All patients received Nexavar (sorafenib). Its therapeutic effectiveness varied from partial response to long-term stabilization. the differentiated thyroid cancer resistant to therapy 131i decision multi-kinase inhibitor nexavar (sorafenib) Neoplasms. Tumors. Oncology. Including cancer and carcinogens P. O. Rumyantsev verfasserin aut V. V. Polkin verfasserin aut A. A. Ilyin verfasserin aut D. Yu. Syomin verfasserin aut T. A. Agababyan verfasserin aut S. V. Vasilkov verfasserin aut V. S. Medvedev verfasserin aut In Опухоли головы и шеи ABV-press, 2016 (2015), 2, Seite 46-50 (DE-627)1760616370 24114634 nnns year:2015 number:2 pages:46-50 https://doi.org/10.17650/2222-1468-2014-0-2-46-50 kostenfrei https://doaj.org/article/a3b54c5c44cc4a929dc1b83bea2764f9 kostenfrei https://ogsh.abvpress.ru/jour/article/view/52 kostenfrei https://doaj.org/toc/2222-1468 Journal toc kostenfrei https://doaj.org/toc/2411-4634 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2015 2 46-50
allfieldsGer	10.17650/2222-1468-2014-0-2-46-50 doi (DE-627)DOAJ085436208 (DE-599)DOAJa3b54c5c44cc4a929dc1b83bea2764f9 DE-627 ger DE-627 rakwb rus RC254-282 P. A. Isaev verfasserin aut CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The treatment choice of differentiated thyroid cancer resistant to therapy 131I to be restricted just to systemic methods. Traditional chemotherapy demonstrated no clinically relevant effectiveness but high toxicity. With the introduction into clinical practice of multi-kinase inhibitor was able to significantly improve treatment outcomes.The paper demonstrated two patients with the incurable of differentiated thyroid cancer resistant to therapy 131I. All patients received Nexavar (sorafenib). Its therapeutic effectiveness varied from partial response to long-term stabilization. the differentiated thyroid cancer resistant to therapy 131i decision multi-kinase inhibitor nexavar (sorafenib) Neoplasms. Tumors. Oncology. Including cancer and carcinogens P. O. Rumyantsev verfasserin aut V. V. Polkin verfasserin aut A. A. Ilyin verfasserin aut D. Yu. Syomin verfasserin aut T. A. Agababyan verfasserin aut S. V. Vasilkov verfasserin aut V. S. Medvedev verfasserin aut In Опухоли головы и шеи ABV-press, 2016 (2015), 2, Seite 46-50 (DE-627)1760616370 24114634 nnns year:2015 number:2 pages:46-50 https://doi.org/10.17650/2222-1468-2014-0-2-46-50 kostenfrei https://doaj.org/article/a3b54c5c44cc4a929dc1b83bea2764f9 kostenfrei https://ogsh.abvpress.ru/jour/article/view/52 kostenfrei https://doaj.org/toc/2222-1468 Journal toc kostenfrei https://doaj.org/toc/2411-4634 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2015 2 46-50
allfieldsSound	10.17650/2222-1468-2014-0-2-46-50 doi (DE-627)DOAJ085436208 (DE-599)DOAJa3b54c5c44cc4a929dc1b83bea2764f9 DE-627 ger DE-627 rakwb rus RC254-282 P. A. Isaev verfasserin aut CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The treatment choice of differentiated thyroid cancer resistant to therapy 131I to be restricted just to systemic methods. Traditional chemotherapy demonstrated no clinically relevant effectiveness but high toxicity. With the introduction into clinical practice of multi-kinase inhibitor was able to significantly improve treatment outcomes.The paper demonstrated two patients with the incurable of differentiated thyroid cancer resistant to therapy 131I. All patients received Nexavar (sorafenib). Its therapeutic effectiveness varied from partial response to long-term stabilization. the differentiated thyroid cancer resistant to therapy 131i decision multi-kinase inhibitor nexavar (sorafenib) Neoplasms. Tumors. Oncology. Including cancer and carcinogens P. O. Rumyantsev verfasserin aut V. V. Polkin verfasserin aut A. A. Ilyin verfasserin aut D. Yu. Syomin verfasserin aut T. A. Agababyan verfasserin aut S. V. Vasilkov verfasserin aut V. S. Medvedev verfasserin aut In Опухоли головы и шеи ABV-press, 2016 (2015), 2, Seite 46-50 (DE-627)1760616370 24114634 nnns year:2015 number:2 pages:46-50 https://doi.org/10.17650/2222-1468-2014-0-2-46-50 kostenfrei https://doaj.org/article/a3b54c5c44cc4a929dc1b83bea2764f9 kostenfrei https://ogsh.abvpress.ru/jour/article/view/52 kostenfrei https://doaj.org/toc/2222-1468 Journal toc kostenfrei https://doaj.org/toc/2411-4634 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2015 2 46-50
language	Russian
source	In Опухоли головы и шеи (2015), 2, Seite 46-50 year:2015 number:2 pages:46-50
sourceStr	In Опухоли головы и шеи (2015), 2, Seite 46-50 year:2015 number:2 pages:46-50
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	the differentiated thyroid cancer resistant to therapy 131i decision multi-kinase inhibitor nexavar (sorafenib) Neoplasms. Tumors. Oncology. Including cancer and carcinogens
isfreeaccess_bool	true
container_title	Опухоли головы и шеи
authorswithroles_txt_mv	P. A. Isaev @@aut@@ P. O. Rumyantsev @@aut@@ V. V. Polkin @@aut@@ A. A. Ilyin @@aut@@ D. Yu. Syomin @@aut@@ T. A. Agababyan @@aut@@ S. V. Vasilkov @@aut@@ V. S. Medvedev @@aut@@
publishDateDaySort_date	2015-01-01T00:00:00Z
hierarchy_top_id	1760616370
id	DOAJ085436208
language_de	russisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ085436208</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410120617.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2015 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17650/2222-1468-2014-0-2-46-50</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ085436208</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJa3b54c5c44cc4a929dc1b83bea2764f9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">P. A. Isaev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The treatment choice of differentiated thyroid cancer resistant to therapy 131I to be restricted just to systemic methods. Traditional chemotherapy demonstrated no clinically relevant effectiveness but high toxicity. With the introduction into clinical practice of multi-kinase inhibitor was able to significantly improve treatment outcomes.The paper demonstrated two patients with the incurable of differentiated thyroid cancer resistant to therapy 131I. All patients received Nexavar (sorafenib). Its therapeutic effectiveness varied from partial response to long-term stabilization.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">the differentiated thyroid cancer resistant to therapy 131i</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">decision</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">multi-kinase inhibitor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nexavar (sorafenib)</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">P. O. Rumyantsev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">V. V. Polkin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. A. Ilyin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D. Yu. Syomin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">T. A. Agababyan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. V. Vasilkov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">V. S. Medvedev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Опухоли головы и шеи</subfield><subfield code="d">ABV-press, 2016</subfield><subfield code="g">(2015), 2, Seite 46-50</subfield><subfield code="w">(DE-627)1760616370</subfield><subfield code="x">24114634</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2015</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:46-50</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17650/2222-1468-2014-0-2-46-50</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/a3b54c5c44cc4a929dc1b83bea2764f9</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ogsh.abvpress.ru/jour/article/view/52</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2222-1468</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2411-4634</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2015</subfield><subfield code="e">2</subfield><subfield code="h">46-50</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	P. A. Isaev
spellingShingle	P. A. Isaev misc RC254-282 misc the differentiated thyroid cancer resistant to therapy 131i misc decision misc multi-kinase inhibitor misc nexavar (sorafenib) misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I
authorStr	P. A. Isaev
ppnlink_with_tag_str_mv	@@773@@(DE-627)1760616370
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC254-282
illustrated	Not Illustrated
issn	24114634
topic_title	RC254-282 CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I the differentiated thyroid cancer resistant to therapy 131i decision multi-kinase inhibitor nexavar (sorafenib)
topic	misc RC254-282 misc the differentiated thyroid cancer resistant to therapy 131i misc decision misc multi-kinase inhibitor misc nexavar (sorafenib) misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_unstemmed	misc RC254-282 misc the differentiated thyroid cancer resistant to therapy 131i misc decision misc multi-kinase inhibitor misc nexavar (sorafenib) misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_browse	misc RC254-282 misc the differentiated thyroid cancer resistant to therapy 131i misc decision misc multi-kinase inhibitor misc nexavar (sorafenib) misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Опухоли головы и шеи
hierarchy_parent_id	1760616370
hierarchy_top_title	Опухоли головы и шеи
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1760616370
title	CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I
ctrlnum	(DE-627)DOAJ085436208 (DE-599)DOAJa3b54c5c44cc4a929dc1b83bea2764f9
title_full	CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I
author_sort	P. A. Isaev
journal	Опухоли головы и шеи
journalStr	Опухоли головы и шеи
callnumber-first-code	R
lang_code	rus
isOA_bool	true
recordtype	marc
publishDateSort	2015
contenttype_str_mv	txt
container_start_page	46
author_browse	P. A. Isaev P. O. Rumyantsev V. V. Polkin A. A. Ilyin D. Yu. Syomin T. A. Agababyan S. V. Vasilkov V. S. Medvedev
class	RC254-282
format_se	Elektronische Aufsätze
author-letter	P. A. Isaev
doi_str_mv	10.17650/2222-1468-2014-0-2-46-50
author2-role	verfasserin
title_sort	clinical experience of nexavar (sorafenib) application in patients with metastatic differentiated thyroid cancer resistant to therapy 131i
callnumber	RC254-282
title_auth	CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I
abstract	The treatment choice of differentiated thyroid cancer resistant to therapy 131I to be restricted just to systemic methods. Traditional chemotherapy demonstrated no clinically relevant effectiveness but high toxicity. With the introduction into clinical practice of multi-kinase inhibitor was able to significantly improve treatment outcomes.The paper demonstrated two patients with the incurable of differentiated thyroid cancer resistant to therapy 131I. All patients received Nexavar (sorafenib). Its therapeutic effectiveness varied from partial response to long-term stabilization.
abstractGer	The treatment choice of differentiated thyroid cancer resistant to therapy 131I to be restricted just to systemic methods. Traditional chemotherapy demonstrated no clinically relevant effectiveness but high toxicity. With the introduction into clinical practice of multi-kinase inhibitor was able to significantly improve treatment outcomes.The paper demonstrated two patients with the incurable of differentiated thyroid cancer resistant to therapy 131I. All patients received Nexavar (sorafenib). Its therapeutic effectiveness varied from partial response to long-term stabilization.
abstract_unstemmed	The treatment choice of differentiated thyroid cancer resistant to therapy 131I to be restricted just to systemic methods. Traditional chemotherapy demonstrated no clinically relevant effectiveness but high toxicity. With the introduction into clinical practice of multi-kinase inhibitor was able to significantly improve treatment outcomes.The paper demonstrated two patients with the incurable of differentiated thyroid cancer resistant to therapy 131I. All patients received Nexavar (sorafenib). Its therapeutic effectiveness varied from partial response to long-term stabilization.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	2
title_short	CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I
url	https://doi.org/10.17650/2222-1468-2014-0-2-46-50 https://doaj.org/article/a3b54c5c44cc4a929dc1b83bea2764f9 https://ogsh.abvpress.ru/jour/article/view/52 https://doaj.org/toc/2222-1468 https://doaj.org/toc/2411-4634
remote_bool	true
author2	P. O. Rumyantsev V. V. Polkin A. A. Ilyin D. Yu. Syomin T. A. Agababyan S. V. Vasilkov V. S. Medvedev
author2Str	P. O. Rumyantsev V. V. Polkin A. A. Ilyin D. Yu. Syomin T. A. Agababyan S. V. Vasilkov V. S. Medvedev
ppnlink	1760616370
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.17650/2222-1468-2014-0-2-46-50
callnumber-a	RC254-282
up_date	2024-07-03T14:44:22.760Z
_version_	1803569450463526912
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ085436208</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410120617.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2015 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17650/2222-1468-2014-0-2-46-50</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ085436208</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJa3b54c5c44cc4a929dc1b83bea2764f9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">P. A. Isaev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The treatment choice of differentiated thyroid cancer resistant to therapy 131I to be restricted just to systemic methods. Traditional chemotherapy demonstrated no clinically relevant effectiveness but high toxicity. With the introduction into clinical practice of multi-kinase inhibitor was able to significantly improve treatment outcomes.The paper demonstrated two patients with the incurable of differentiated thyroid cancer resistant to therapy 131I. All patients received Nexavar (sorafenib). Its therapeutic effectiveness varied from partial response to long-term stabilization.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">the differentiated thyroid cancer resistant to therapy 131i</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">decision</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">multi-kinase inhibitor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nexavar (sorafenib)</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">P. O. Rumyantsev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">V. V. Polkin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. A. Ilyin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D. Yu. Syomin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">T. A. Agababyan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. V. Vasilkov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">V. S. Medvedev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Опухоли головы и шеи</subfield><subfield code="d">ABV-press, 2016</subfield><subfield code="g">(2015), 2, Seite 46-50</subfield><subfield code="w">(DE-627)1760616370</subfield><subfield code="x">24114634</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2015</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:46-50</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17650/2222-1468-2014-0-2-46-50</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/a3b54c5c44cc4a929dc1b83bea2764f9</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ogsh.abvpress.ru/jour/article/view/52</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2222-1468</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2411-4634</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2015</subfield><subfield code="e">2</subfield><subfield code="h">46-50</subfield></datafield></record></collection>
score	7.4021063

Nicht das Richtige dabei?

Schreiben Sie uns!

CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?